ACOD1 and neoplasm: To confirm the anti-tumor therapeutic effect, we established a B16-F10-OVA tumor model, and 5 μg OVA-LNP, si-Irg1-LNP, or OVA&si-Irg1-LNP was administered subcutaneously on day 7 when the tumor volume reached 50mm3, and a boost dose was given on day 12 (Figure 6A).